Modified polymerases for improved incorporation of nucleotide analogues

US9447389B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9447389-B2
Application numberUS-201414476387-A
CountryUS
Kind codeB2
Filing dateSep 3, 2014
Priority dateSep 11, 2003
Publication dateSep 20, 2016
Grant dateSep 20, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to modified polymerase enzymes which exhibit improved incorporation of nucleotide analogs bearing substituents at the 3′ position of the sugar moiety that are larger in size than the naturally occurring 3′ hydroxyl group. Also described are methods of using the polymerases to incorporate nucleotides into polynucleotides, particularly in the context of DNA sequencing.

First claim

Opening claim text (preview).

The invention claimed is: 1. An altered Vent DNA polymerase, wherein the second amino acid of the motif A region is mutated to alanine (A); and the third amino acid of the motif A region is mutated to an amino acid selected from the group consisting of serine (S), alanine (A), glycine (G), and the amino acids having beta-branched side chains, whereby the altered Vent DNA polymerase is capable of incorporating a 3′ O-azidomethyl-modified nucleotide. 2. The polymerase according to claim 1 , which exhibits an increased rate of incorporation of the modified nucleotides, compared to a wild type Vent DNA polymerase, an exo-variant of wild type Vent DNA polymerase, or a wild type or exo-variant of wild type having one or more of the following additional mutations: Y412V, Y412L, Y412F, Q486E, Q486L, R487K, A488C, A488S, A488L, A488I, A488F, A488V, K490A, K490R, K490N, N494D, S495A, Y496F, Y496L, Y497S, Y497F, Y499L, Y499F, A488C/Y499F or A488L/Y499L. 3. The polymerase according to claim 1 , wherein the third amino acid of the motif A region is mutated to isoleucine (I), threonine (T), valine (V) or leucine (L). 4. The polymerase according to claim 1 , wherein the third amino acid of the motif A region is mutated to serine (S), alanine (A) or glycine (G). 5. The polymerase according to claim 1 , further comprising an amino acid substitution mutation at the first amino acid of the motif A region selected from tyrosine (Y), phenylalanine (F), isoleucine (I), alanine (A), valine (V), glutamine (Q), cysteine (C) or serine (S). 6. The polymerase according to claim 1 , wherein the polymerase lacks 3′-5′ exonuclease activity. 7. The polymerase according to claim 1 , further comprising at least one amino acid substitution mutation in the motif B region, whereby the activity of the polymerase is enhanced. 8. The polymerase according to claim 7 , wherein the substitution mutation in the motif B region is to the second amino acid. 9. The polymerase according to claim 8 , wherein the substitution mutation is to an amino acid selected from the group consisting of F, I, S, V and C. 10. The polymerase according to claim 8 , wherein the substitution mutation is to L. 11. The polymerase according to claim 7 , wherein the motif B substitution mutations are to G at the first amino acid position and L at the third. 12. The polymerase according to claim 7 , wherein the motif B substitution mutations are to N at the first amino acid position and Q at the third. 13. The polymerase according to claim 7 , wherein the motif B substitution mutations are to those substitutions selected from the group consisting of SKN, GRD, KHN, ISN and THH. 14. The polymerase according to claim 1 , further comprising at least one substitution mutation in the motif C region. 15. The polymerase according to claim 14 , wherein the motif C region comprises at least one substitution mutation.

Assignees

Inventors

Classifications

  • C12N9/1252Primary

    DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

  • DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

  • Methods for sequencing · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9447389B2 cover?
The invention relates to modified polymerase enzymes which exhibit improved incorporation of nucleotide analogs bearing substituents at the 3′ position of the sugar moiety that are larger in size than the naturally occurring 3′ hydroxyl group. Also described are methods of using the polymerases to incorporate nucleotides into polynucleotides, particularly in the context of DNA sequencing.
Who is the assignee on this patent?
Illumina Cambridge Ltd
What technology area does this patent fall under?
Primary CPC classification C12N9/1252. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).